{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:17:38Z","timestamp":1778887058513,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s12094-020-02398-4","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T07:02:42Z","timestamp":1590649362000},"page":"92-99","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Long intergenic non-coding RNA-p21 is associated with poor prognosis in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2113-3569","authenticated-orcid":false,"given":"R.","family":"Abo Elwafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Abd Elrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Ghallab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2398_CR1","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.24826","volume":"92","author":"M Hallek","year":"2017","unstructured":"Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946\u201365.","journal-title":"Am J Hematol"},{"issue":"Suppl 5","key":"2398_CR2","doi-asserted-by":"publisher","first-page":"v162","DOI":"10.1093\/annonc\/mdq180","volume":"21","author":"B Eichhorst","year":"2010","unstructured":"Eichhorst B, Hallek M, Dreyling M. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v162\u2013v164164.","journal-title":"Ann Oncol"},{"key":"2398_CR3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804\u201315.","journal-title":"N Engl J Med"},{"key":"2398_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nrclinonc.2009.72","volume":"6","author":"L Pleyer","year":"2009","unstructured":"Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009;6:405\u201318.","journal-title":"Nat Rev Clin Oncol"},{"key":"2398_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cancergencyto.2010.09.007","volume":"203","author":"SP Nana-Sinkam","year":"2010","unstructured":"Nana-Sinkam SP, Croce CM. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet. 2010;203:127\u201333.","journal-title":"Cancer Genet Cytogenet"},{"key":"2398_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1182\/asheducation-2015.1.368","volume":"2015","author":"S Stilgenbauer","year":"2015","unstructured":"Stilgenbauer S. Prognostic markers and standard management of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:368\u201377.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2398_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/nat.2012.0414","volume":"23","author":"Y Sanchez","year":"2013","unstructured":"Sanchez Y, Huarte M. Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther. 2013;23:15\u201320.","journal-title":"Nucleic Acid Ther"},{"key":"2398_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2014.04.002","volume":"762","author":"X Li","year":"2014","unstructured":"Li X, Wu Z, Fu X, Han W. lncRNAs: insights into their function and mechanics in underlying disorders. Mutat Res Rev Mutat Res. 2014;762:1\u201321.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"2398_CR9","doi-asserted-by":"publisher","first-page":"e1000459","DOI":"10.1371\/journal.pgen.1000459","volume":"5","author":"JS Mattick","year":"2009","unstructured":"Mattick JS. The genetic signatures of noncoding RNAs. PLoS Genet. 2009;5:e1000459.","journal-title":"PLoS Genet"},{"key":"2398_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.cell.2010.06.040","volume":"142","author":"M Huarte","year":"2010","unstructured":"Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142:409\u201319.","journal-title":"Cell"},{"key":"2398_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cca.2014.02.010","volume":"431","author":"M Isin","year":"2014","unstructured":"Isin M, Ozgur E, Cetin G, et al. Investigation of circulating lncRNAs in B-cell neoplasms. Clin Chim Acta. 2014;431:255\u20139.","journal-title":"Clin Chim Acta"},{"key":"2398_CR12","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.clcc.2013.06.003","volume":"12","author":"H Zhai","year":"2013","unstructured":"Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer. 2013;12:261\u20136.","journal-title":"Clin Colorectal Cancer"},{"key":"2398_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.molcel.2012.06.027","volume":"47","author":"JH Yoon","year":"2012","unstructured":"Yoon JH, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47:648\u201355.","journal-title":"Mol Cell"},{"key":"2398_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s12032-017-0959-5","volume":"34","author":"S Chen","year":"2017","unstructured":"Chen S, Liang H, Yang H, et al. LincRNa-p21: function and mechanism in cancer. Med Oncol. 2017;34:98.","journal-title":"Med Oncol"},{"key":"2398_CR15","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"key":"2398_CR16","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"2398_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","volume":"38","author":"CA Rodrigues","year":"2016","unstructured":"Rodrigues CA, Goncalves MV, Ikoma MR, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter. 2016;38:346\u201357.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"2398_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2553.x","volume":"77","author":"K Karrman","year":"2006","unstructured":"Karrman K, Andersson A, Bjorgvinsdottir H, et al. Deregulation of cyclin D2 by juxtaposition with T-cell receptor alpha\/delta locus in t(12;14)(p13;q11)-positive childhood T-cell acute lymphoblastic leukemia. Eur J Haematol. 2006;77:27\u201334.","journal-title":"Eur J Haematol"},{"key":"2398_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cancergencyto.2010.08.009","volume":"203","author":"SA Smoley","year":"2010","unstructured":"Smoley SA, Van Dyke DL, Kay NE, et al. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. Cancer Genet Cytogenet. 2010;203:141\u20138.","journal-title":"Cancer Genet Cytogenet"},{"key":"2398_CR20","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"2398_CR21","first-page":"253","volume-title":"Chronic lymphocytic leukemia: recent progress and future directions","author":"KR Rai","year":"1987","unstructured":"Rai KR. A critical analysis of staging in CLL. In: Gale RPRK, editor. Chronic lymphocytic leukemia: recent progress and future directions. New York: Liss; 1987. p. 253\u2013264."},{"key":"2398_CR22","doi-asserted-by":"publisher","first-page":"25942","DOI":"10.18632\/oncotarget.15401","volume":"8","author":"CR Miller","year":"2017","unstructured":"Miller CR, Ruppert AS, Fobare S, et al. The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget. 2017;8:25942\u201354.","journal-title":"Oncotarget"},{"key":"2398_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452\u201363.","journal-title":"Cancer Cell"},{"key":"2398_CR24","doi-asserted-by":"publisher","first-page":"e12318","DOI":"10.1111\/cpr.12318","volume":"50","author":"X Wang","year":"2017","unstructured":"Wang X, Ruan Y, Zhao W, et al. Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer. Cell Prolif. 2017;50:e12318. https:\/\/doi.org\/10.1111\/cpr.12318.","journal-title":"Cell Prolif"},{"key":"2398_CR25","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.jtho.2016.07.015","volume":"11","author":"JJ Castellano","year":"2016","unstructured":"Castellano JJ, Navarro A, Vinolas N, et al. LincRNA-p21 impacts prognosis in resected non-small cell lung cancer patients through angiogenesis regulation. J Thorac Oncol. 2016;11:2173\u201382.","journal-title":"J Thorac Oncol"},{"key":"2398_CR26","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1038\/leu.2015.119","volume":"29","author":"CJ Blume","year":"2015","unstructured":"Blume CJ, Hotz-Wagenblatt A, Hullein J, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 2015;29:2015\u201323.","journal-title":"Leukemia"},{"key":"2398_CR27","doi-asserted-by":"publisher","first-page":"16708","DOI":"10.3390\/ijms131216708","volume":"13","author":"A Baldassarre","year":"2012","unstructured":"Baldassarre A, Masotti A. Long non-coding RNAs and p53 regulation. Int J Mol Sci. 2012;13:16708\u201317.","journal-title":"Int J Mol Sci"},{"key":"2398_CR28","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1073\/pnas.0904715106","volume":"106","author":"AM Khalil","year":"2009","unstructured":"Khalil AM, Guttman M, Huarte M, et al. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA. 2009;106:11667\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2398_CR29","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.4161\/cc.10.14.16588","volume":"10","author":"K Kuribayashi","year":"2011","unstructured":"Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS. The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo. Cell Cycle. 2011;10:2380\u20139.","journal-title":"Cell Cycle"},{"key":"2398_CR30","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1038\/sj.emboj.7601359","volume":"25","author":"T Shibue","year":"2006","unstructured":"Shibue T, Suzuki S, Okamoto H, et al. Differential contribution of Puma and Noxa in dual regulation of p53-mediated apoptotic pathways. EMBO J. 2006;25:4952\u201362.","journal-title":"EMBO J"},{"key":"2398_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","volume":"21","author":"JE Guikema","year":"2017","unstructured":"Guikema JE, Amiot M, Eldering E. Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opin Ther Targets. 2017;21:767\u201379.","journal-title":"Expert Opin Ther Targets"},{"key":"2398_CR32","doi-asserted-by":"publisher","first-page":"28151","DOI":"10.18632\/oncotarget.4661","volume":"6","author":"N Yang","year":"2015","unstructured":"Yang N, Fu Y, Zhang H, Sima H, Zhu N, Yang G. LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma. Oncotarget. 2015;6:28151\u201363.","journal-title":"Oncotarget"},{"key":"2398_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1182\/asheducation-2010.1.77","volume":"2010","author":"RR Furman","year":"2010","unstructured":"Furman RR. Prognostic markers and stratification of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program. 2010;2010:77\u201381.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2398_CR34","doi-asserted-by":"publisher","first-page":"602","DOI":"10.5858\/arpa.2014-0086-RA","volume":"139","author":"EC Chastain","year":"2015","unstructured":"Chastain EC, Duncavage EJ. Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma. Arch Pathol Lab Med. 2015;139:602\u20137.","journal-title":"Arch Pathol Lab Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-020-02398-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-020-02398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:14:31Z","timestamp":1622164471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-020-02398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1007\/s12094-020-02398-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted after approval of the Medical Ethics Committee of Alexandria Faculty of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All study participants gave written informed consents after explaining the nature, steps and aim of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}